Avid Bioservices, Inc. (CDMO) - Net earnings per one share growth for the current year

Corporate emblem and logo of Avid Bioservices Inc (CDMO)

Nick Green's experienced leadership has driven order book growth and secured fund confidence for Avid Bioservices, Inc. (CDMO). The annual EPS trend reflects the market valuation of assets, where the 0.00 mark indicates the current consensus level. Business stability is based on long-term B2B contracts with industry behemoths and the implementation of automated drug purification systems that minimize personnel costs.

CDMO Avid Bioservices Earnings growth in current year (07/04/2022 - 02/16/2025)

Financial and market metric breakdowns for Avid Bioservices Inc. (CDMO)

- current quotes and average value forecast:
Fundamental valuation:Avid Bioservices, Inc.
Finished products of Avid Bioservices

Avid Bioservices, Inc. (CDMO) operational successes in the biologics contract manufacturing segment are clearly reflected in the YoY net income per share growth rate. This indicator measures the annual EPS growth rate, capturing the real efficiency of monetizing the rising demand for mammalian cell cultures. A steady upward trend confirms the business's scalability, although sharp fluctuations may signal that the company has reached its production capacity limits.